The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

J.J. Cornelissen; A. Gratwohl; R.F. Schlenk; J. Sierra; M. Bornhaeuser; G. Juliusson; Z. Racil; J.M. Rowe; N. Russell; M. Mohty; B. Lowenberg; G. Socie; D. Niederwieser; G.J. Ossenkoppele

doi:https://doi.org/10.1038/nrclinonc.2012.150

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

J.J. Cornelissen, A. Gratwohl, R.F. Schlenk, J. Sierra, M. Bornhaeuser, G. Juliusson, Z. Racil, J.M. Rowe, N. Russell, M. Mohty, B. Lowenberg, G. Socie, D. Niederwieser, G.J. Ossenkoppele

Hematology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

318 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	579-590
Journal	Nature Reviews Clinical Oncology
Volume	9
Issue number	10
DOIs	https://doi.org/10.1038/nrclinonc.2012.150
Publication status	Published - 2012

Access to Document

https://doi.org/10.1038/nrclinonc.2012.150

Cite this

Cornelissen, J. J., Gratwohl, A., Schlenk, R. F., Sierra, J., Bornhaeuser, M., Juliusson, G., Racil, Z., Rowe, J. M., Russell, N., Mohty, M., Lowenberg, B., Socie, G., Niederwieser, D., & Ossenkoppele, G. J. (2012). The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 9(10), 579-590. https://doi.org/10.1038/nrclinonc.2012.150

@article{b8bfef83a1bd48aeaa5ecd99e4de1ce9,

title = "The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach",

author = "J.J. Cornelissen and A. Gratwohl and R.F. Schlenk and J. Sierra and M. Bornhaeuser and G. Juliusson and Z. Racil and J.M. Rowe and N. Russell and M. Mohty and B. Lowenberg and G. Socie and D. Niederwieser and G.J. Ossenkoppele",

year = "2012",

doi = "https://doi.org/10.1038/nrclinonc.2012.150",

language = "Undefined/Unknown",

volume = "9",

pages = "579--590",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "10",

}

Cornelissen, JJ, Gratwohl, A, Schlenk, RF, Sierra, J, Bornhaeuser, M, Juliusson, G, Racil, Z, Rowe, JM, Russell, N, Mohty, M, Lowenberg, B, Socie, G, Niederwieser, D & Ossenkoppele, GJ 2012, 'The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach', Nature Reviews Clinical Oncology, vol. 9, no. 10, pp. 579-590. https://doi.org/10.1038/nrclinonc.2012.150

TY - JOUR

T1 - The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

AU - Cornelissen, J.J.

AU - Gratwohl, A.

AU - Schlenk, R.F.

AU - Sierra, J.

AU - Bornhaeuser, M.

AU - Juliusson, G.

AU - Racil, Z.

AU - Rowe, J.M.

AU - Russell, N.

AU - Mohty, M.

AU - Lowenberg, B.

AU - Socie, G.

AU - Niederwieser, D.

AU - Ossenkoppele, G.J.

PY - 2012

Y1 - 2012

U2 - https://doi.org/10.1038/nrclinonc.2012.150

DO - https://doi.org/10.1038/nrclinonc.2012.150

M3 - Article

C2 - 22949046

SN - 1759-4774

VL - 9

SP - 579

EP - 590

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 10

ER -